Total hip replacement (THR) and total knee replacement (TKR) are common and effective interventions for degenerative joint conditions, such as osteoarthritis.
1 Venous thromboembolism (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [PE]) is an important cause of long-term morbidity, represents a preventable cause of mortality, and has substantial health care costs.
2 All patients undergoing joint replacement are at risk of VTE because of the duration of surgery and reduced perioperative mobility. To reduce VTE risk, almost all patients receive up to 35 days of anticoagulation after surgery.
3 Rates of VTE at 90 days after THR and TKR are variable (up to 5% for DVT and up to 2% for PE in anticoagulated patients).
4